11:52 AM EDT, 03/25/2025 (MT Newswires) -- Organovo ( ONVO ) said Tuesday that it has completed the sale of its farnesoid X receptor, or FXR, program to Eli Lilly ( LLY ) .

The agreement was announced in February, with Organovo ( ONVO ) saying it will sell the FXR program for an upfront payment of $10 million and potential milestone payments of up to $50 million.

Eli Lilly ( LLY ) has now acquired all commercial and intellectual property rights to the FXR program and will be responsible for its future clinical development.

Price: 2.92, Change: -0.07, Percent Change: -2.34